Friday, October 31, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term

by Staff Correspondent
August 16, 2022
in Markets
Reading Time: 3 mins read
A A
0
Home Markets
Share on FacebookShare on Twitter


Shares of Pfizer Inc. (NYSE: PFE) have been down on Monday. The inventory has dropped 15% year-to-date and there’s a blended sentiment surrounding the corporate’s development prospects. Pfizer has benefited considerably from its COVID-19 merchandise. Whereas there are issues over the longevity of those COVID-related positive aspects and the efficiency of its non-COVID portfolio, there may be additionally a normal sense of optimism that the corporate shall be simply high quality given its income and pipeline. Right here’s a take a look at the headwinds and tailwinds this pharma big faces:

Tailwinds

Pfizer has seen robust performances from its COVID-19 merchandise they usually made up the vast majority of its revenues in its most up-to-date quarter. Comirnaty, its COVID-19 vaccine, generated $8.8 billion in gross sales for the second quarter of 2022, reflecting a year-over-year development of 20%, whereas Paxlovid, its oral COVID-19 therapy, generated $8.1 billion in gross sales. The contributions from these merchandise helped drive a 47% YoY development in complete income to $27.7 billion.

The specter of COVID is anticipated to proceed within the close to time period as infections rise and new variants emerge. On this state of affairs, there shall be a requirement for booster vaccines which in flip may increase Pfizer’s income. For FY2022, Pfizer expects Comirnaty to generate revenues of approx. $32 billion and Paxlovid to yield revenues of approx. $22 billion.

Though its COVID-19 merchandise type a big a part of its income, Pfizer is just not totally depending on them. The corporate has a big portfolio of merchandise that assist drive significant revenues exterior the COVID-19 area. Through the second quarter, Pfizer witnessed double-digit development in merchandise just like the Prevnar household, Eliquis and Vyndaqel/Vyndamax.

The corporate additionally has a strong pipeline of merchandise in growth for varied indications together with a number of myeloma and ulcerative colitis. As soon as authorised, these will generate further income and drive additional development.

Pfizer can be increasing its portfolio by means of acquisitions. In Could, the corporate introduced the acquisition of Biohaven Prescribed drugs, which can carry Biohaven’s migraine therapies beneath the Pfizer umbrella. Pfizer has additionally introduced plans to amass International Blood Therapeutics, which can develop its presence in uncommon hematology and provides it entry to the latter’s portfolio and pipeline in sickle cell illness, which has the potential to generate worldwide peak gross sales of greater than $3 billion.

Headwinds  

The truth that a good portion of Pfizer’s income got here from its COVID-19 merchandise has raised issues over the corporate’s high line development as soon as the pandemic subsides and demand for this explicit class dips. Pfizer’s income, excluding Comirnaty and Paxlovid, elevated just one% in Q2. The corporate has additionally seen double-digit gross sales declines for a few of its merchandise like Xeljanz and Sutent because of value declines and lack of exclusivity. These components have raised issues over the corporate’s development prospects over the long run.

Click on right here to learn the complete transcript of Pfizer’s Q2 2022 earnings convention name



Source link

Tags: FacesgiantHeadwindsPFEPfizerPharmaTailwindsTerm
Previous Post

The Philosophy of the Pseudoprogressives

Next Post

KKR to sell entire 26% Max Healthcare stake for Rs 9,416 crore today

Related Posts

The Internet Just Got Its Own Money

The Internet Just Got Its Own Money

by Ian King
October 31, 2025
0

Ten years in the past, essentially the most influential banker of the twenty first century — Jamie Dimon — proclaimed...

SPX Technologies anticipates M Olympus Max bookings and raises 2025 EPS outlook amid strong segment growth (NYSE:SPXC)

SPX Technologies anticipates $50M Olympus Max bookings and raises 2025 EPS outlook amid strong segment growth (NYSE:SPXC)

by SA Transcript Insights Editor
October 31, 2025
0

Looking for Alpha's Disclaimer: The earnings name insights are compilations of earnings name transcripts and different content material out there...

Apple Q4 revenue grows on higher iPhone sales; results beat estimates

Apple Q4 revenue grows on higher iPhone sales; results beat estimates

by Staff Correspondent
October 31, 2025
0

Apple Inc. (NASDAQ: AAPL) reported a rise in gross sales for the fourth quarter of fiscal 2025, primarily reflecting continued...

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

by Michelle Fox
October 30, 2025
0

It has been a stellar few months for shares of San Francisco-based biotech firm Rigel Prescribed drugs, which has accredited...

Xi-Trump meeting sparks optimism in China — but many wonder what comes next

Xi-Trump meeting sparks optimism in China — but many wonder what comes next

by Evelyn Cheng
October 30, 2025
0

A display screen exhibits information footage of the bilateral assembly between Chinese language President Xi Jinping and U.S. President Donald...

Will AI Kill the Corporation?

Will AI Kill the Corporation?

by Ian King
October 30, 2025
0

For greater than 4 centuries, the company has been the central engine of capitalism. From the Dutch East India Firm...

Next Post
KKR to sell entire 26% Max Healthcare stake for Rs 9,416 crore today

KKR to sell entire 26% Max Healthcare stake for Rs 9,416 crore today

Biden, Democrats suddenly have a lot of good stuff to run on for the midterms, and a plan to use it

Biden, Democrats suddenly have a lot of good stuff to run on for the midterms, and a plan to use it

Alerus Financial Corporation (ALRS) Q3 2025 Earnings Call Transcript

Alerus Financial Corporation (ALRS) Q3 2025 Earnings Call Transcript

October 31, 2025
The Internet Just Got Its Own Money

The Internet Just Got Its Own Money

October 31, 2025
Disney pulls ABC, ESPN and more from YouTube TV as talks break down

Disney pulls ABC, ESPN and more from YouTube TV as talks break down

October 31, 2025
Windows Remote Desktop goes immersive as Meta Quest 3 adds mixed-reality workspaces

Windows Remote Desktop goes immersive as Meta Quest 3 adds mixed-reality workspaces

October 31, 2025
Toyota To Debut All-Electric “bZ Time Attack” AWD Concept At 2025 SEMA Show

Toyota To Debut All-Electric “bZ Time Attack” AWD Concept At 2025 SEMA Show

October 31, 2025
US to Create Task Force-Philippines to Enhance Operations in South China Sea

US to Create Task Force-Philippines to Enhance Operations in South China Sea

October 31, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Alerus Financial Corporation (ALRS) Q3 2025 Earnings Call Transcript

The Internet Just Got Its Own Money

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In